CRISPR Therapeutics Stock Surges on FDA-Approved Drug Sales Growth
Source Summary
CRISPR Therapeutics' stock gained significantly following strong sales performance of an FDA-approved drug it helped develop. The drug achieved a nearly 80% sequential increase in sales.
Why it matters
Strong sequential sales growth of an FDA-approved therapeutic directly drove investor confidence and stock performance for the company.
